Beneficial effect of enalapril in spontaneously hypertensive rats cardiac remodeling with nitric oxide synthesis blockade

Aims. To study the efficiency of an angiotensin converting enzyme inhibitor on the blood pressure (BP) and the myocardium remodeling when spontaneously hypertensive rats (SHRs) are submitted to nitric oxide synthesis (NOs) blockade (with L‐NAME) and simultaneously treated.

[1]  K. Metze,et al.  Chronic nitric oxide inhibition as a model of hypertensive heart muscle disease , 1996, Basic Research in Cardiology.

[2]  G. Wallukat,et al.  Inducible nitric oxide synthase in the myocard , 2004, Molecular and Cellular Biochemistry.

[3]  C. Mandarim-de-Lacerda,et al.  Stereology of cardiac hypertrophy induced by NO blockade in rats treated with enalapril and verapamil. , 2001, Analytical and quantitative cytology and histology.

[4]  Y. Hirooka,et al.  Role of Nitric Oxide in Central Sympathetic Outflow , 2001, Experimental biology and medicine.

[5]  B. Kone.  Molecular biology of natriuretic peptides and nitric oxide synthases. , 2001, Cardiovascular research.

[6]  C. Mandarim-de-Lacerda,et al.  Renal cortical remodelling by NO‐synthesis blockers in rats is prevented by angiotensin‐converting enzyme inhibitor and calcium channel blocker , 2001, Journal of cellular and molecular medicine.

[7]  C. Johnston,et al.  Effect of angiotensin-converting enzyme inhibition on myocardial vascularization in the adolescent and adult spontaneously hypertensive rat , 2001, Journal of hypertension.

[8]  A. Jurjus,et al.  A comparative study of morphological changes in spontaneously hypertensive rats and normotensive Wistar Kyoto rats treated with an angiotensin‐converting enzyme inhibitor or a calcium‐channel blocker , 2001, The Journal of pathology.

[9]  C. Mandarim-de-Lacerda,et al.  Influence of the chronic nitric oxide synthesis inhibition on cardiomyocytes number , 2000, Virchows Archiv.

[10]  K. Weber,et al.  Targeting pathological remodeling: concepts of cardioprotection and reparation. , 2000, Circulation.

[11]  C. Brilla.  Renin-angiotensin-aldosterone system and myocardial fibrosis. , 2000, Cardiovascular research.

[12]  V. Pelouch,et al.  Regression of chronic L -NAME-treatment-induced left ventricular hypertrophy: effect of captopril. , 2000, Journal of molecular and cellular cardiology.

[13]  C. Mandarim-de-Lacerda,et al.  Numerical Density of Cardiomyocytes in Chronic Nitric Oxide Synthesis Inhibition , 2000, Pathobiology.

[14]  C. Mandarim-de-Lacerda,et al.  Effect of antihypertensive drugs on the myocardial microvessels in rats with nitric oxide blockade. , 2000, Pathology, research and practice.

[15]  O. Pechanova,et al.  Induction of angiogenesis in NO-deficient rat heart. , 2000, Physiological research.

[16]  F. Simko,et al.  The potential role of nitric oxide in the hypertrophic growth of the left ventricle. , 2000, Physiological research.

[17]  C. Mandarim-de-Lacerda,et al.  Volume-weighted mean nuclear volume and numerical nuclear density in the cardiomyocyte following enalapril and verapamil treatment , 2000, Virchows Archiv.

[18]  C. Lagrasta,et al.  Recent advances in cardiac hypertrophy. , 2000, Cardiovascular research.

[19]  O. Pechanova,et al.  Effect of Captopril in L‐Name‐Induced Hypertension on the Rat Myocardium, Aorta, Brain and Kidney , 1999, Experimental physiology.

[20]  T. Fujimori,et al.  Apoptosis, coronary arterial remodeling, and myocardial infarction after nitric oxide inhibition in SHR. , 1999, Hypertension.

[21]  E. Abdel-Rahman,et al.  Angiotensin II and nitric oxide: a question of balance , 1999, Regulatory Peptides.

[22]  J. Bishop,et al.  Regulation of cardiovascular collagen synthesis by mechanical load. , 1999, Cardiovascular research.

[23]  C. Mandarim-de-Lacerda,et al.  Stereology and Immunohistochemistry of the Myocardium in Experimental Hypertension: Long-Term and Low-Dosage Administration of Inhibitor of the Nitric Oxide Synthesis , 1999, Pathobiology.

[24]  C. Mandarim-de-Lacerda,et al.  Myocardial microcirculation stereological changes in rats subjected to nitric oxide synthesis inhibition. , 1999, Pathology, research and practice.

[25]  T. Kahan.  The importance of left ventricular hypertrophy in human hypertension. , 1998, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[26]  Y. Pinto,et al.  Lessons from rat models of hypertension: from Goldblatt to genetic engineering. , 1998, Cardiovascular research.

[27]  S. Doggrell,et al.  Rat models of hypertension, cardiac hypertrophy and failure. , 1998, Cardiovascular research.

[28]  J. S. Janicki,et al.  Left ventricular adaptation to chronic pressure overload induced by inhibition of nitric oxide synthase in rats , 1998, Basic Research in Cardiology.

[29]  G. Parati,et al.  Limitations of the difference between clinic and daytime blood pressure as a surrogate measure of the ‘white‐coat’ effect , 1998, Journal of hypertension.

[30]  M. Paul,et al.  Hypertension and the renin-angiotensin system – evidence from genetic and transgenic studies , 1998, Basic Research in Cardiology.

[31]  K. Weber,et al.  Metabolic responses of extracellular matrix in tissue repair. , 1997, Annals of medicine.

[32]  P. Babál,et al.  Chronic inhibition of NO synthesis produces myocardial fibrosis and arterial media hyperplasia. , 1997, Histology and histopathology.

[33]  S. Moncada.  Nitric Oxide in the Vasculature: Physiology and Pathophysiology , 1997, Annals of the New York Academy of Sciences.

[34]  M. Copland,et al.  Basal nitric oxide synthesis in essential hypertension , 1997, The Lancet.

[35]  A. Takeshita,et al.  Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. , 1997, The Journal of clinical investigation.

[36]  E. Agabiti-Rosei,et al.  Effects of Angiotensin-Converting Enzyme Inhibitors on the Heart and Vessels in Clinical and Experimental Hypertension , 1996 .

[37]  K. Weber,et al.  Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis. , 1996, Hypertension.

[38]  O. Pechanova,et al.  Captopril prevents NO-deficient hypertension and left ventricular hypertrophy without affecting nitric oxide synthase activity in rats. , 1996, Physiological research.

[39]  V. Znojil,et al.  Morphometric characteristics of cardiac hypertrophy induced by long-term inhibition of NO synthase. , 1996, Physiological research.

[40]  T. Imaizumi,et al.  Chronic L-arginine administration attenuates cardiac hypertrophy in spontaneously hypertensive rats. , 1996, Hypertension.

[41]  K. Metze,et al.  Enalapril does not prevent the myocardial ischemia caused by the chronic inhibition of nitric oxide synthesis. , 1995, European journal of pharmacology.

[42]  A. Takeshita,et al.  Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. , 1995, Hypertension.

[43]  E. Frohlich,et al.  Nitric oxide synthase inhibition in spontaneously hypertensive rats. Systemic, renal, and glomerular hemodynamics. , 1995, Hypertension.

[44]  K. Rakušan,et al.  Effect of nifedipine on coronary capillary geometry in normotensive and hypertensive rats. , 1994, Hypertension.

[45]  A. Ooshima,et al.  Remodelling of microvessels by coronary hypertension or cardiac hypertrophy in rats. , 1994, Journal of molecular and cellular cardiology.

[46]  J. Ménard,et al.  Cardiac weight in hypertension induced by nitric oxide synthase blockade. , 1993, Hypertension.

[47]  Y. Nitta,et al.  REMODELING OF MICROVESSELS BY CORONARY HYPERTENSION OR CARDIAC HYPERTROPHY IN RATS , 1993 .

[48]  Y. Akada,et al.  Effects of Ethyl all‐cis-5,8,11,14,17‐Icosapentaenoate on the Physical Properties of Arterial Walls in High Cholesterol Diet‐Fed Rabbits , 1993, Journal of cardiovascular pharmacology.

[49]  E. Ongini,et al.  Spirapril Prevents Left Ventricular Hypertrophy, Decreases Myocardial Damage and Promotes Angiogenesis in Spontaneously Hypertensive Rats , 1993, Journal of cardiovascular pharmacology.

[50]  B. Folkow.  Early structural changes in hypertension: pathophysiology and clinical consequences. , 1993, Journal of cardiovascular pharmacology.

[51]  T. Mattfeldt,et al.  Effect of early onset angiotensin converting enzyme inhibition on myocardial capillaries. , 1992, Hypertension.

[52]  P. Sanders,et al.  L-arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. , 1991, The Journal of clinical investigation.

[53]  F. B. Sørensen.  Stereological estimation of the mean and variance of nuclear volume from vertical sections , 1991, Journal of microscopy.

[54]  E R Weibel,et al.  Recent stereological methods for cell biology: a brief survey. , 1990, The American journal of physiology.

[55]  J. Clozel,et al.  Effects of chronic ACE inhibition on cardiac hypertrophy and coronary vascular reserve in spontaneously hypertensive rats with developed hypertension. , 1989, Journal of hypertension.

[56]  S. Moncada,et al.  Vascular endothelial cells synthesize nitric oxide from L-arginine , 1988, Nature.

[57]  S. Moncada,et al.  Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor , 1987, Nature.

[58]  H. Gundersen,et al.  Stereological estimation of the volume‐weighted mean volume of arbitrary particles observed on random sections * , 1985, Journal of microscopy.

[59]  R. Furchgott,et al.  The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine , 1980, Nature.

[60]  G. Lindley.  HYPERTENSION; EVALUATION AND TREATMENT. , 1965, Texas state journal of medicine.

[61]  K. Okamoto,et al.  Development of a strain of spontaneously hypertensive rats. , 1963, Japanese circulation journal.